Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma With Major Portal Vein Invasion

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2017

Conditions
Hepatocellular CarcinomaPortal Vein Tumor Thrombus
Interventions
RADIATION

Stereotactic ablative radiotherapy

"The HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein) will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 40 Gy in 4 fractionations. Patients receive 4 fractionations separated by \>48 hours.~At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of \> 19.2 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of \> 19.2 Gy. Dose of spinal cord do not exceed 26 Gy. Dose of esophagus, stomach and intestine do not exceed 35 Gy."

Trial Locations (8)

660-702

Gyeongsang National University Hospital, Jinju

Unknown

Dongnam Institute of Radiological & Medical Sciences, Busan

Catholic University Incheon St. Mary's Hospital, Incheon

Inha University Hospital, Incheon

Soon Chun Hyang University Hospital Seoul, Seoul

700-712

Keimyung University Dongsan Medical Center, Daegu

110-744

Seoul National University Hospital, Seoul

139-706

Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul

All Listed Sponsors
collaborator

Seoul National University Hospital

OTHER

collaborator

Dongnam Institute of Radiological & Medical Sciences

OTHER

collaborator

Soon Chun Hyang University

OTHER

collaborator

Inha University Hospital

OTHER

collaborator

Incheon St.Mary's Hospital

OTHER

collaborator

Gyeongsang National University Hospital

OTHER

collaborator

Keimyung University Dongsan Medical Center

OTHER

lead

Korea Cancer Center Hospital

OTHER

NCT01850368 - Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma With Major Portal Vein Invasion | Biotech Hunter | Biotech Hunter